WRAPSODY Cell-Impermeable Endoprosthesis
Merit Medical Systems, Inc. · Decision date Jun 11, 2026
What did the FDA decide?
FDA records P240023/S005 as a supplement to PMA P240023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 11, 2026.
FDA approval order statement
a duplicate manufacturing line for the Wrapsody Cell-Impermeable Endoprosthesis
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jun 11, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240023/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Merit Medical Systems, Inc.
- Product code
- PFV
- Decision code
- OK30
- Decision date
- Jun 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.
- Applicant
- Merit Medical Systems, Inc.
- Product code
- PFV
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P240023/S004 · Related supplement
WRAPSODY Cell-Impermeable Endoprosthesis
P240023/S005 received
Application receipt date recorded by FDA.
P240023/S005 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P240023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
WRAPSODY Cell-Impermeable EndoprosthesisP240023/S004 | Merit Medical Systems, Inc. | PMA supplement | Dec 11, 2025 | FDA |
Explore the linked device profile
Other records with product code PFV
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Fluency Plus Endovascular Stent GraftP130029/S015 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 22, 2026 | FDA |
Bard Fluency Plus Endovascular Stent GraftP130029/S014 | Bard Peripheral Vascular, Inc. | PMA supplement | Jun 10, 2026 | FDA |
Covera Vascular Covered StentP170042/S015 | C.R. Bard, Inc. | PMA supplement | Jun 10, 2026 | FDA |
| W. L. Gore & Associates, Inc. | PMA supplement | May 26, 2026 | FDA | |
Covera Vascular Covered StentP170042/S014 | C.R. Bard, Inc. | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merit Medical Systems, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1600 W. Merit Pkwy., South Jordan, UT, 84095
Sources and methodology
- Original FDA record: P240023/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



